StockDuty ← Dashboard Sep 05, 2026 12:25 PM ET
SignalFDA/Bio

Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback

Phase 3 setback and fully valued assessment signal negative catalyst for RARE.

Phase 3 setback and fully valued assessment signal negative catalyst for RARE.
Sources